Dec 13, 2012 by Max MacalusoThe Best of 2012: AffymaxAffymax's drug treating anemia in dialysis patients was FDA approved this year, and is now a major threat to the competition. That has shares up nearly 270% for the year, making Affymax #11 on our list of the very best healthcare stocks of 2012.
Dec 13, 2012 by Max MacalusoThe Best of 2012: Threshold PharmaceuticalsHigh expectations for Threshold Pharmaceuticals' new drug in the treatment of pancreatic cancer have seen shares skyrocket 262% this year, making the company #12 on our list of the best performing healthcare stocks of 2012.
Dec 13, 2012 by Max MacalusoThe Best of 2012: PharmacyclicsEnthusiasm over this company's experimental cancer drug has made investors a mint this year; the stock is up 258%, making Pharmacyclics #13 on our list of the very best healthcare stocks of 2012.
Dec 13, 2012 by Max MacalusoThe Best of 2012: Regeneron PharmaceuticalsRegeneron's stellar success in the macular degeneration space has the stock up an incredible 218.5% for the year, putting this company at No. 14 on our list of the very best healthcare stocks of 2012.
Dec 13, 2012 by Max MacalusoThe Best of 2012: Repros TherapeuticsNo long-term debt and an impressive drug in the pipeline has left Repros Therapeutics up 211% this year, reaching No. 15 on our list of the very best healthcare stocks of 2012.
Dec 10, 2012 by Max Macaluso and Brenton FlynnIs This the Start of a VIVUS Comeback?VIVUS shares rebounded 4% today. Is this the resurgence investors were hoping for?
Dec 10, 2012 by Max Macaluso and Brenton FlynnIs Geron's Latest Strategy Good News for Investors?After a tough year, Geron finally has a bit of good news today.
Dec 10, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: Progenics PharmaceuticalsAnd now, the very worst stock in all of the healthcare sector for 2012, falling a crippling 72.4% this year, Progenics Pharmaceuticals.
Dec 10, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: Chelsea TherapeuticsComing in at No. 2 on our list of the very worst healthcare stocks of 2012, a company that faced a big FDA rejection earlier this year, Chelsea Therapeutics.
Dec 10, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: AVEO PharmaceuticalsAt #3 on our list of the very worst healthcare stocks of 2012, makers of the kidney cancer drug Tivozanib, AVEO Pharmaceuticals.
Dec 10, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: ZELTIQ AestheticsAt No. 4 on our list of the very worst healthcare stocks of 2012, ZELTIQ Aesthetics is a very illustrative case of what can happen when management sets guidance a little too optimistically.
Dec 10, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: Corcept TherapeuticsNearing the end of our list of the very worst healthcare stocks of 2012, at No. 5 is Corcept Therapeutics, which came into 2012 like a lion and is going out like a lamb.
Dec 6, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: BioTimeContinuing our countdown of the very worst healthcare stocks of 2012, BioTime comes in at No. 20.
Dec 6, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: Pacific Biosciences of CaliforniaContinuing our countdown of the very worst healthcare stocks of 2012, at No. 16, Pacific Biosciences of California.
Dec 6, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: OncothyreonHere, we continue our look at the very worst health care stocks of 2012. Next up, Oncothyreon, at No. 17.
Dec 6, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: AtriCureAtriCure is No. 18 on our list of the very worst health care stocks of 2012.
Dec 6, 2012 by Max Macaluso and Brenton FlynnThe Worst of 2012: Momenta PharmaceuticalsMomenta Pharmaceuticals is #19 on our list of the very worst stocks of 2012 in the health care sector.
Dec 4, 2012 by Max Macaluso and Brenton FlynnMore Bad News for Geron?The departure of Geron's CFO is far from the worst of its troubles.
Dec 4, 2012 by Max Macaluso and Brenton FlynnWhy This Biotech Shakeup Didn't Stir InvestorsPDL BioPharma's CFO has resigned. Why didn't the market bat an eye?
